Prospective Grant of Start-Up Exclusive Evaluation Option License Agreement: A3 Adenosine Receptor (A3AR) Agonists as an Orally-Administered Analgesic for Treatment of Chronic Neuropathic Pain, 73091-73092 [2014-28749]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Parkinson’s Disease
Biomarker Program.
Date: December 17, 2014.
Time: 2:30 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Shanta Rajaram, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Boulevard, Suite 3208, MSC
9529, Bethesda, MD 20892–9529, 301–435–
6033, rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: December 3, 2014.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–28753 Filed 12–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
rljohnson on DSK3VPTVN1PROD with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Sep<11>2014
14:48 Dec 08, 2014
Jkt 235001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Cancer Health Disparities/Diversity in Basic
Cancer Research.
Date: December 8–9, 2014.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Rolf Jakobi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7806, Bethesda, MD 20892, 301–495–
1718, jakobir@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: AIDS and AIDS Related Research.
Date: December 9, 2014.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Robert Freund, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5216,
MSC 7852, Bethesda, MD 20892, 301–435–
1050, freundr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR Panel:
Multidisciplinary Studies of HIV and Viral
Hepatitis Co-Infection.
Date: December 10, 2014.
Time: 12:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Shiv A. Prasad, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5220,
MSC 7852, Bethesda, MD 20892, 301–443–
5779, prasads@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Fellowships: AIDS and AIDS Related
Applications.
Date: December 11, 2014.
Time: 10:00 a.m. to 6:00 p.m.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
73091
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Mary Clare Walker, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5208,
MSC 7852, Bethesda, MD 20892, (301) 435–
1165, walkermc@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 3, 2014.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–28751 Filed 12–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up
Exclusive Evaluation Option License
Agreement: A3 Adenosine Receptor
(A3AR) Agonists as an OrallyAdministered Analgesic for Treatment
of Chronic Neuropathic Pain
AGENCY:
National Institutes of Health,
HHS
ACTION:
Notice
This is notice, in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
that the National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of a
Start-Up Exclusive Evaluation Option
License Agreement to BioIntervene, Inc.,
a company having a place of business in
Saint Louis, Missouri to practice the
inventions embodied in the following
patent applications and patents:
1. U.S. Patent 8,735,407, issued May
27, 2014, titled ‘‘Purine Derivatives As
A3 Adenosine Receptor-Selective
Agonists’’ [HHS Ref. No. E–140–2008/0–
US–06];
2. European Patent Application
09728154.7, filed March 24, 2009, titled
‘‘Purine Derivatives As A3 Adenosine
Receptor-Selective Agonists’’ [HHS Ref.
No. E–140–2008/0–EP–05];
3. Canadian Patent Application
2720037, filed March 24, 2009, titled
‘‘Purine Derivatives As A3 Adenosine
Receptor-Selective Agonists’’ [HHS Ref.
No. E–140–2008/0–CA–04];
SUMMARY:
E:\FR\FM\09DEN1.SGM
09DEN1
rljohnson on DSK3VPTVN1PROD with NOTICES
73092
Federal Register / Vol. 79, No. 236 / Tuesday, December 9, 2014 / Notices
4. Australian Patent 2009231978,
issued February 20, 2014, titled ‘‘Purine
Derivatives As A3 Adenosine ReceptorSelective Agonists’’ [HHS Ref. No. E–
140–2008/0–AU–03];
5. U.S. Patent Application 13/371,081,
filed February 10, 2012, titled ‘‘A3
Adenosine Receptor Agonists And
Antagonists’’ [HHS Ref. No. E–140–
2008/1–US–01];
6. U.S. Provisional Application 61/
909,742, filed November 27, 2013, titled
‘‘A3 Adenosine Receptor Agonists’’
[HHS Ref. No. E–742–2013/0–US–01];
and
7. U.S. Provisional Application 62/
033,723, filed August 6, 2014, titled ‘‘A3
Adenosine Receptor Agonists’’ [HHS
Ref. No. E–210–2014/0–US–01].
The patent rights in these inventions
either have been assigned to the
Government of the United States of
America, or have been granted exclusive
rights to the Government of the United
States of America. The territory of the
prospective Start-up Exclusive
Evaluation Option License Agreement
may be worldwide, and the field of use
may be limited to: ‘‘The use of an A3
Adenosine Receptor (A3AR) agonist as
an orally-administered analgesic, either
as monotherapy or as an add-on
analgesic, for treatment of chronic
neuropathic pain conditions’’.
Upon the expiration or termination of
the Start-up Exclusive Evaluation
Option License Agreement,
BioIntervene will have the exclusive
right to execute a Start-up Exclusive
Patent License Agreement which will
supersede and replace the Start-up
Exclusive Evaluation Option License
Agreement, with no greater field of use
and territory than granted in the Startup Exclusive Evaluation Option License
Agreement.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
December 24, 2014 will be considered.
ADDRESSES: Requests for copies of the
patents, patent applications, inquiries,
comments, and other materials relating
to the contemplated Start-Up Exclusive
Evaluation Option License Agreement
should be directed to: Betty B. Tong,
Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 594–6565; Facsimile: (301) 402–
0220; Email: tongb@mail.nih.gov. A
signed confidentiality nondisclosure
agreement will be required to receive
copies of any patent applications that
have not been published or issued by
VerDate Sep<11>2014
14:48 Dec 08, 2014
Jkt 235001
the United States Patent and Trademark
Office or the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: The
subject inventions describe selective A3
Adenosine Receptor (A3AR) agonists,
and their in vivo activity reducing or
preventing development of chronic
neuropathic pain in an animal model.
The A3AR subtype was linked with
helping protect the heart from ischemia,
controlling inflammation, and
regulating cell proliferation. The
compounds claimed are consistently
highly selective and have smaller
molecular weight, thus can offer greater
oral bioavailability. Hence, the subject
inventions may provide a new treatment
for chronic neuropathic pain.
The prospective Start-up Exclusive
Evaluation Option License Agreement
and a subsequent Start-up Exclusive
Patent License Agreement may be
granted unless the NIH receives written
evidence and argument, within fifteen
(15) days from the date of this published
notice, that establishes that the grant of
the contemplated Start-up Exclusive
Evaluation Option License Agreement
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are filed
in response to this notice will be treated
as objections to the grant of the
contemplated Start-Up Exclusive
Evaluation Option License Agreement.
Comments and objections submitted in
response to this notice will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 3, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2014–28749 Filed 12–8–14; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615–0030]
Agency Information Collection
Activities: Application for Waiver of the
Foreign Residence Requirement of
Section 212(e) of the Immigration and
Nationality Act, Form I–612; Revision
of a Currently Approved
ACTION:
PO 00000
30-Day Notice.
Frm 00067
Fmt 4703
Sfmt 4703
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration Services (USCIS) will be
submitting the following information
collection request to the Office of
Management and Budget (OMB) for
review and clearance in accordance
with the Paperwork Reduction Act of
1995. The information collection notice
was previously published in the Federal
Register on September 10, 2014, at 79
FR 53720, allowing for a 60-day public
comment period. USCIS did receive 1
comment in connection with the 60-day
notice.
DATES: The purpose of this notice is to
allow an additional 30 days for public
comments. Comments are encouraged
and will be accepted until January 8,
2015. This process is conducted in
accordance with 5 CFR 1320.10.
ADDRESSES: Written comments and/or
suggestions regarding the item(s)
contained in this notice, especially
regarding the estimated public burden
and associated response time, must be
directed to the OMB USCIS Desk Officer
via email at oira_submission@
omb.eop.gov. Comments may also be
submitted via fax at (202) 395–5806. All
submissions received must include the
agency name and the OMB Control
Number 1615–0030.
You may wish to consider limiting the
amount of personal information that you
provide in any voluntary submission
you make. For additional information
please read the Privacy Act notice that
is available via the link in the footer of
https://www.regulations.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Comments:
Note: The address listed in this notice
should only be used to submit
comments concerning this information
collection. Please do not submit
requests for individual case status
inquiries to this address. If you are
seeking information about the status of
your individual case, please check ‘‘My
Case Status’’ online at: https://
egov.uscis.gov/cris/Dashboard.do, or
call the USCIS National Customer
Service Center at 1–800–375–5283.
Written comments and suggestions
from the public and affected agencies
should address one or more of the
following four points:
(1) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(2) Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
E:\FR\FM\09DEN1.SGM
09DEN1
]]>Agencies
[Federal Register Volume 79, Number 236 (Tuesday, December 9, 2014)]
[Notices]
[Pages 73091-73092]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-28749]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Start-Up Exclusive Evaluation Option License
Agreement: A3 Adenosine Receptor (A3AR) Agonists as an Orally-
Administered Analgesic for Treatment of Chronic Neuropathic Pain
AGENCY: National Institutes of Health, HHS
ACTION: Notice
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR
part 404, that the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of a Start-Up Exclusive
Evaluation Option License Agreement to BioIntervene, Inc., a company
having a place of business in Saint Louis, Missouri to practice the
inventions embodied in the following patent applications and patents:
1. U.S. Patent 8,735,407, issued May 27, 2014, titled ``Purine
Derivatives As A3 Adenosine Receptor-Selective Agonists'' [HHS Ref. No.
E-140-2008/0-US-06];
2. European Patent Application 09728154.7, filed March 24, 2009,
titled ``Purine Derivatives As A3 Adenosine Receptor-Selective
Agonists'' [HHS Ref. No. E-140-2008/0-EP-05];
3. Canadian Patent Application 2720037, filed March 24, 2009,
titled ``Purine Derivatives As A3 Adenosine Receptor-Selective
Agonists'' [HHS Ref. No. E-140-2008/0-CA-04];
[[Page 73092]]
4. Australian Patent 2009231978, issued February 20, 2014, titled
``Purine Derivatives As A3 Adenosine Receptor-Selective Agonists'' [HHS
Ref. No. E-140-2008/0-AU-03];
5. U.S. Patent Application 13/371,081, filed February 10, 2012,
titled ``A3 Adenosine Receptor Agonists And Antagonists'' [HHS Ref. No.
E-140-2008/1-US-01];
6. U.S. Provisional Application 61/909,742, filed November 27,
2013, titled ``A3 Adenosine Receptor Agonists'' [HHS Ref. No. E-742-
2013/0-US-01]; and
7. U.S. Provisional Application 62/033,723, filed August 6, 2014,
titled ``A3 Adenosine Receptor Agonists'' [HHS Ref. No. E-210-2014/0-
US-01].
The patent rights in these inventions either have been assigned to
the Government of the United States of America, or have been granted
exclusive rights to the Government of the United States of America. The
territory of the prospective Start-up Exclusive Evaluation Option
License Agreement may be worldwide, and the field of use may be limited
to: ``The use of an A3 Adenosine Receptor (A3AR) agonist as an orally-
administered analgesic, either as monotherapy or as an add-on
analgesic, for treatment of chronic neuropathic pain conditions''.
Upon the expiration or termination of the Start-up Exclusive
Evaluation Option License Agreement, BioIntervene will have the
exclusive right to execute a Start-up Exclusive Patent License
Agreement which will supersede and replace the Start-up Exclusive
Evaluation Option License Agreement, with no greater field of use and
territory than granted in the Start-up Exclusive Evaluation Option
License Agreement.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
December 24, 2014 will be considered.
ADDRESSES: Requests for copies of the patents, patent applications,
inquiries, comments, and other materials relating to the contemplated
Start-Up Exclusive Evaluation Option License Agreement should be
directed to: Betty B. Tong, Ph.D., Senior Licensing and Patenting
Manager, Office of Technology Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804;
Telephone: (301) 594-6565; Facsimile: (301) 402-0220; Email:
tongb@mail.nih.gov. A signed confidentiality nondisclosure agreement
will be required to receive copies of any patent applications that have
not been published or issued by the United States Patent and Trademark
Office or the World Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The subject inventions describe selective A3
Adenosine Receptor (A3AR) agonists, and their in vivo activity reducing
or preventing development of chronic neuropathic pain in an animal
model. The A3AR subtype was linked with helping protect the heart from
ischemia, controlling inflammation, and regulating cell proliferation.
The compounds claimed are consistently highly selective and have
smaller molecular weight, thus can offer greater oral bioavailability.
Hence, the subject inventions may provide a new treatment for chronic
neuropathic pain.
The prospective Start-up Exclusive Evaluation Option License
Agreement and a subsequent Start-up Exclusive Patent License Agreement
may be granted unless the NIH receives written evidence and argument,
within fifteen (15) days from the date of this published notice, that
establishes that the grant of the contemplated Start-up Exclusive
Evaluation Option License Agreement would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the prospective field of use
that are filed in response to this notice will be treated as objections
to the grant of the contemplated Start-Up Exclusive Evaluation Option
License Agreement. Comments and objections submitted in response to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 3, 2014.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of
Health.
[FR Doc. 2014-28749 Filed 12-8-14; 8:45 am]
BILLING CODE 4140-01-P
